Pharmacogenetics: Opportunities and Challenges for Health Innovation

Nonfiction, Science & Nature, Science
Cover of the book Pharmacogenetics: Opportunities and Challenges for Health Innovation by Collective, OECD
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: Collective ISBN: 9789264076808
Publisher: OECD Publication: November 12, 2009
Imprint: OECD Language: English
Author: Collective
ISBN: 9789264076808
Publisher: OECD
Publication: November 12, 2009
Imprint: OECD
Language: English

Pharmacogenetics helps us understand the relationship between an individual’s genetic make-up and the way medicines work for each person. This book reviews the use of pharmacogenetics across all stages of the health innovation cycle from research through to uptake by doctors and patients. It focuses on how to optimise the use of pharmacogenetics to deliver effective innovations for public health, and design policies that enhance their economic and social benefits. The book argues for large-scale studies to validate the biomarkers that underpin pharmacogenetics and policies to share the cost and risk of using pharmacogenetics to improve the use of existing medicines. Governments and others need to align regulatory, reimbursement and other incentives and work with industry to measure better the impacts of pharmacogenetics. Health systems need to take positive steps to adapt to the use of pharmacogenetics and ensure that health professionals receive adequate training.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Pharmacogenetics helps us understand the relationship between an individual’s genetic make-up and the way medicines work for each person. This book reviews the use of pharmacogenetics across all stages of the health innovation cycle from research through to uptake by doctors and patients. It focuses on how to optimise the use of pharmacogenetics to deliver effective innovations for public health, and design policies that enhance their economic and social benefits. The book argues for large-scale studies to validate the biomarkers that underpin pharmacogenetics and policies to share the cost and risk of using pharmacogenetics to improve the use of existing medicines. Governments and others need to align regulatory, reimbursement and other incentives and work with industry to measure better the impacts of pharmacogenetics. Health systems need to take positive steps to adapt to the use of pharmacogenetics and ensure that health professionals receive adequate training.

More books from OECD

Cover of the book OECD Investment Policy Reviews: India 2009 by Collective
Cover of the book Perspectives agricoles de l'OCDE et de la FAO 2009 by Collective
Cover of the book OECD Economic Surveys: Ireland 2009 by Collective
Cover of the book Interrelations between Public Policies, Migration and Development in Costa Rica by Collective
Cover of the book OECD Economic Surveys: South Africa 2010 by Collective
Cover of the book Making Development Co-operation Work for Small Island Developing States by Collective
Cover of the book OECD Environmental Performance Reviews: Finland 2009 by Collective
Cover of the book Measuring Innovation by Collective
Cover of the book Panorama des comptes nationaux 2010 by Collective
Cover of the book Southeast Asian Economic Outlook 2010 by Collective
Cover of the book Regulatory Policy in Slovenia by Collective
Cover of the book The Impact of the Financial Crisis on the Insurance Sector and Policy Responses by Collective
Cover of the book Multi-dimensional Review of Peru by Collective
Cover of the book Open for Business by Collective
Cover of the book Green Growth Indicators 2017 by Collective
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy